DMII Overview

Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. While the Company may pursue a business combination target in any business, industry or geographical location, it intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenue to date.

Wall Street analysts forecast DMII stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DMII is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Drugs Made In America Acquisition II Corp revenue for the last quarter amounts to -1.05M USD, decreased

Drugs Made In America Acquisition II Corp. EPS for the last quarter amounts to -314864.00 USD, decreased

Drugs Made In America Acquisition II Corp (DMII) has 0 emplpoyees as of May 01 2026.

Today DMII has the market capitalization of 638.27M USD.